Orforglipron (Foundayo)

Orforglipron changes everything about how people access GLP-1 therapy. While semaglutide and tirzepatide are complex peptides requiring cold chain storage and weekly injection, orforglipron is a small-molecule pill that can be taken once daily at any time, with or without food, stored at room temperature. This addresses the three biggest barriers to GLP-1 adoption: needle aversion, cold chain logistics, and cost. The molecule was developed by Eli Lilly and received FDA approval on April 1, 2026, for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. It was the fastest new molecular entity approval since 2002, processed in just 50 days through the Commissioner's National Priority Voucher pilot program. As a non-peptide small molecule, orforglipron is completely different from existing GLP-1 drugs. Peptide-based GLP-1 agonists like semaglutide require elaborate chemical modifications (fatty acid chains, amino acid substitutions) to survive in the body long enough to work. Oral semaglutide (Rybelsus) needs a specialized absorption enhancer (SNAC), strict fasting, and achieves only about 1% oral bioavailability. Orforglipron sidesteps all of this because small molecules are inherently resistant to protease degradation and can be absorbed efficiently throughout the GI tract. The Phase 3 ATTAIN program established orforglipron's efficacy. ATTAIN-1 (NEJM 2025) enrolled 3,127 adults with obesity and showed dose-dependent weight loss: 7.5% (6 mg), 8.4% (12 mg), and 11.2% (36 mg) versus 2.1% placebo at 72 weeks. ATTAIN-2 (Lancet 2025) tested orforglipron in 1,600+ adults with obesity and type 2 diabetes, achieving 10.5% weight loss and 1.8% HbA1c reduction at 36 mg. The trade-off is clear: orforglipron produces less weight loss than injectable alternatives (11% vs 15-22% for semaglutide/tirzepatide), but it is far more accessible. At $149/month introductory and $299-349/month maintenance through LillyDirect, it costs a fraction of branded injectables. With commercial insurance, it starts at $25/month. Medicare beneficiaries pay $50/month. Side effects follow the GLP-1 class pattern: nausea, vomiting, diarrhea, and constipation, predominantly during dose escalation. Discontinuation rates ranged from 5.3-10.3% across dose groups versus 2.7% for placebo. Some evidence suggests GI side effects may be less frequent than with injectable GLP-1s, possibly because the shorter half-life (25-68 hours vs 5-7 days for injectables) allows faster washout if adverse effects occur. Orforglipron is not a peptide and was not affected by any peptide compounding regulations. As a newly approved small-molecule drug, standard pharmaceutical compounding rules apply. Additional Phase 3 trials are ongoing for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease, and stress urinary incontinence.